35 / 210
Ponencias
35
Conclusión
Durante los últimos 10 años se han producido importantes
avances en patología plaquetaria. Algunos, plenamente consoli-
dados y que han supuesto una nueva era tanto en la expansión y
progreso diagnóstico de alteraciones congénitas de las plaquetas
facilitado por las técnicas de secuenciación profunda, como en el
cambio en el tratamiento de pacientes con PTI tras la incorporación
en el arsenal terapéutico de los agonistas del receptor de la TPO.
Hemos asistido también a un uso casi indiscriminado del empleo
de PRP en diversas patologías, fundamentalmente en cirugía orto-
pédica, en ausencia de ensayos bien diseñados que lo justifiquen.
Los resultados de ensayos clínicos de terapia antiplaquetaria en la
prevención del cáncer exigen llevar a cabo esfuerzos multidiscipli-
nares que realmente establezcan el papel de estos agentes en este
campo. Aunque el empleo de terapias celulares con megacariocitos
y plaquetas procedentes de células
stem
abre muchas posibilidades
terapéuticas, se espera que un mayor recorrido y conocimiento de
estas aproximaciones permitan establecer en los próximos años su
potencial aplicación en diferentes escenarios clínicos.
Bibliografía
1. Albers CA, Cvejic A, Favier R, Bouwmans EE, Alessi MC, Bertone
P, et al. Exome sequencing identifies NBEAL2 as the causative gene
for gray platelet syndrome. Nat Genet 2011;43:735-7.
2. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, Zivony-Elboum Y,
Gumruk F, Cetin M, et al. NBEAL2 is mutated in gray platelet syn-
drome and is required for biogenesis of platelet
α
-granules. Nat
Genet 2011;43:732-4.
3. Kahr WH, Hinckley J, Li L, Schwertz H, Christensen H, Rowley JW,
et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray
platelet syndrome. Nat Genet 2011;43:738-40.
4. Sánchez-Guiu I, AntónAI, Padilla J, Velasco F, Lucia JF, Lozano M,
et al. Functional and molecular characterization of inherited platelet
disorders in the Iberian Peninsula: results from a collaborative study.
Orphanet J Rare Dis 2014;24;9:213.
5. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB,
Senecal FM, et al. Efficacy of romiplostim in patients with chro-
nic immune thrombocytopenic purpura: a double-blind randomized
controlled trial. Lancet 2008;371:395-403.
6. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al.
Effect of eltrombopag on platelet counts and bleeding during treat-
ment of chronic idiopathic thrombocytopenic purpura: a randomized,
double blind, placebo-controlled trial. Lancet 2009;373:641-8.
7. Lozano ML, Revilla N, González-López TJ, Novelli S, Gonzá-
lez-Porras JR, Sánchez-González B, et al. Real-life management
of primary immune thrombocytopenia (ITP) in adult patients and
adherence to practice guidelines. Ann Hematol 2016;Apr 21. [Epub
ahead of print].
8. Porteilje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand A.
Morbidity and mortality in adults with idiopathic thrombocytopenic
purpura. Blood 2001;97:2549-54.
9. Khan M, Bedi A. Cochrane in CORR (®): Platelet-rich Therapies
for Musculoskeletal Soft Tissue Injuries (Review). Clin Orthop Relat
Res 2015;473:2207-13.
10. Sheth U, Simunovic N, Klein G, Fu F, Einhorn TA, Schemitsch E,
et al. Efficacy of autologous platelet-rich plasma use for orthopaedic
indications: a meta-analysis. J Bone Joint SurgAm 2012;94:298-307.
11. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA,
et al. 2016 ACC/AHA Guideline Focused Update on Duration of
Dual Antiplatelet Therapy in Patients With CoronaryArtery Disease:
A Report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines: An Update
of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coro-
nary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery
Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/
STS Guideline for the Diagnosis and Management of Patients With
Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the
Management of ST-Elevation Myocardial Infarction, 2014 AHA/
ACC Guideline for the Management of Patients With Non-ST-Ele-
vation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline
on Perioperative Cardiovascular Evaluation and Management of
Patients Undergoing Noncardiac Surgery. Circulation.2016 Mar 29.
pii: CIR.0000000000000404. [Epub ahead of print].
12. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated
with platelet reduction. Proc Natl Acad Sci U S A 1968;61:46-52.
13. Kolenich JJ, Mansour EG, Flynn A. Haematological effects of aspi-
rin. Lancet 1972 30;2:714.
14. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC,
Tognoni G, et al. Short-term effects of daily aspirin on cancer inci-
dence, mortality, and non-vascular death: analysis of the time cour-
se of risks and benefits in 51 randomised controlled trials. Lancet
2012;379:1602-12.
15. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade
TW. Effect of daily aspirin on long-term risk of death due to cancer:
analysis of individual patient data from randomised trials. Lancet
2011;377:31-41.
16. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Meh-
ta Z. Effect of daily aspirin on risk of cancer metastasis: a study
of incident cancers during randomised controlled trials. Lancet
2012;379:1591-601.
17. Bowers LW, Máximo IX, Brenner AJ, BeeramM, Hursting SD, Price
RS, et al. NSAID use reduces breast cancer recurrence in overwei-
ght and obese women: role of prostaglandin-aromatase interactions.
Cancer Res 2014;74:4446-57.
18. Sullivan SK, Mills JA, Koukouritaki SB, Vo KK, Lyde RB, Paluru
P, et al. High-level transgene expression in induced pluripotent stem
cell-derived megakaryocytes: correction of Glanzmann thrombasthe-
nia. Blood 2014;123:753-7.
19. Hirata S, Takayama N, Jono-Ohnishi R, Endo H, Nakamura S,
Dohda T, et al. Congenital amegakaryocytic thrombocytopenia
iPS cells exhibit defective MPL-mediated signaling. J Clin Invest
2013;123:3802-14.
20. López-Onieva L, Montes R, Lamolda M, Romero T, Ayllón V, Loza-
no ML, et al. Generation of induced pluripotent stem cells (iPSCs)
from a Bernard–Soulier syndrome patient carrying aW71R mutation
in the GPIX gene. Stem Cell Res 2016; 3:692-5.
21. Chen Y, Schroeder JA, Kuether EL, Zhang G, Shi Q. Platelet gene
therapy by lentiviral gene delivery to hematopoietic stem cells resto-
res hemostasis and induces humoral immune tolerance in FIX(null)
mice. Mol Ther 2014;22:169-77.
22. Shi Q, Kuether EL, Chen Y, Schroeder JA, Fahs SA, Montgo-
mery RR. Platelet gene therapy corrects the hemophilic pheno-
type in immunocompromised hemophilia A mice transplanted
with genetically manipulated human cord blood stem cells. Blood
2014;123:395-403.
23. Dai M, Han J, El-Amouri SS, Brady RO, Pan D. Platelets are effi-
cient and protective depots for storage, distribution, and delivery of
lysosomal enzyme in mice with Hurler syndrome. Proc Natl Acad
Sci U S A 2014;111:2680-5.